Article thumbnail

Correlation of enhanced thrombospondin-1 expression, TGF-β signalling and proteinuria in human type-2 diabetic nephropathy

By Bernd Hohenstein, Christoph Daniel, Birgit Hausknecht, Kirsten Boehmer, Regine Riess, Kerstin U. Amann and Christian P. M. Hugo

Abstract

Background. Activation of the thrombospondin-1 (TSP-1)-TGF-β pathway by glucose and the relevance of TSP-1-dependent activation of TGF-β for renal matrix expansion, renal fibrosis and sclerosis have previously been demonstrated by our group in in vivo and in vitro studies

Topics: Clinical Nephrology
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2639063
Provided by: PubMed Central

Suggested articles

Citations

  1. (2000). Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev
  2. (2003). Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo.
  3. (2007). Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol
  4. (2007). DanielC,SchaubK,AmannKetal.Thrombospondin-1isanendogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes
  5. (2003). Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol
  6. (1996). Diabetic nephropathy in type II diabetes.
  7. (1999). GilbertRE,CooperME.Thetubulointerstitiuminprogressivediabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int
  8. (2005). Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia
  9. (2000). Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1.
  10. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854–859 Received for publication: 21.10.07 Accepted in revised form:
  11. (1999). Molecular mechanisms of diabetic renal hypertrophy. Kidney Int
  12. (1996). mRNA in patients with diabetes mellitus.
  13. (2005). Protein kinase Cbeta inhibition attenuatesosteopontinexpression,macrophagerecruitment,andtubulointerstitial injury in advanced experimental diabetic nephropathy.
  14. (2000). Role of transforming growth factor beta in human disease.
  15. (2007). TGF-beta in renal injury and disease. Semin Nephrol
  16. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factorbeta. JB i o lC h e m1999;
  17. (1979). The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol
  18. (1998). Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int
  19. (2004). Thrombospondin-1 is a major activatorofTGF-betainfibroticrenaldiseaseintheratinvivo.Kidney Int
  20. (2001). Thrombospondins as matricellular modulators of cell function.
  21. (1998). Transforming growth factor-beta in renal disease.
  22. (2004). Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res
  23. (2001). Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. Nephrol Dial Transplant

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.